Androgenetic alopecia

This phase 3 trial tests whether a daily 1 mg minoxidil pill can treat female pattern hair loss as effectively as the standard topical minoxidil solution. About 520 women with hair thinning will be randomly assigned to receive either the oral pill, the topical solution, or a plac…

This study tests an oral drug called VDPHL01 in 552 women aged 18–65 with mild to moderate hereditary hair loss. Participants take a pill once or twice daily for about 13 months. The goal is to see if it increases hair count and if women feel their hair looks better. It's a place…

This Phase 3 trial tests an oral drug called VDPHL01 in 480 men aged 18-65 with mild to moderate male pattern baldness. The study is double-blind and placebo-controlled, lasting about 13 months. Researchers will measure hair counts and patient satisfaction at 6 months to see if t…

This Phase 2 study tests an investigational oral drug called VDPHL01 in 70 adults with mild to moderate pattern baldness. Participants take a tablet once or twice daily for 12 months. Researchers will measure changes in hair count and ask participants about perceived benefit. The…

This study tests an experimental oral drug called VDPHL01 for male pattern baldness (androgenetic alopecia). About 480 men aged 18 to 65 with mild to moderate hair loss will take either the drug or a placebo for 6 months, then all will receive the active drug for another 6 months…

This trial aimed to test a combination of platelet-rich plasma and stem cells from fat tissue for treating male and female pattern hair loss. It was designed to compare different mixtures injected into the scalp. However, the study was withdrawn before enrolling any participants,…

This study tests a dietary supplement containing taurine, L-cysteine, and grape seed extract to see if it improves hair health in people with hair loss. About 239 men and women will take either the active supplement or a placebo daily for 6 months. Researchers will measure hair d…